Alphabet's Calico Inks $571M Deal with Mabwell for Anti-Aging Asset

Calico Life Sciences, a biotech company under Alphabet's umbrella, has entered into a significant licensing agreement with China-based Mabwell Bioscience. The deal, potentially worth up to $571 million, centers around investigational IL-11 directed therapeutics, including a promising clinical-stage monoclonal antibody for age-related diseases.

Deal Structure and Financial Terms

The agreement involves an upfront payment of $25 million from Calico to Mabwell, with the potential for additional milestone payments bringing the total value to $571 million. This exclusive licensing deal grants Calico the rights to develop and commercialize the assets in all regions except greater China.

Focus on 9MW3811

The primary asset in this deal is 9MW3811, a monoclonal antibody currently in Phase 1 trials across China and Australia. Mabwell has highlighted the potential of this mAb in treating idiopathic pulmonary fibrosis, showcasing its promise in addressing age-related conditions.

Notably, Mabwell has an active investigational new drug application with the FDA for 9MW3811, potentially paving the way for future clinical trials in the United States.

Strategic Implications for Calico

This partnership aligns closely with Calico's mission to understand the biology of aging and develop interventions for longer, healthier lives. Founded by Alphabet and industry veteran Arthur Levinson, Ph.D., Calico has been actively expanding its portfolio of collaborations, which already includes partnerships with AbbVie and the Broad Institute of MIT and Harvard.

The acquisition of rights to 9MW3811 and related IL-11 directed therapeutics represents a significant addition to Calico's pipeline, potentially accelerating its efforts in the anti-aging therapeutic space.